PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29260192
OWN - NLM
STAT- MEDLINE
DCOM- 20171227
LR  - 20171227
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Linking)
VI  - 58
IP  - 14
DP  - 2017 Dec 1
TI  - Patchy Chorioretinal Atrophy Changes at the Posterior Pole After Ranibizumab for 
      Myopic Choroidal Neovascularization.
PG  - 6358-6364
LID - 10.1167/iovs.17-22633 [doi]
AB  - Purpose: To investigate the potential role of ranibizumab treatment on the
      development or enlargement of chorioretinal atrophy (CRA) at the posterior pole
      in eyes with myopic choroidal neovascularization (mCNV). Methods: This
      observational case series included patients having high myopia spherical
      equivalent refractive error >/= -6.00 diopters, axial length (AxL) >/= 26.0 mm in
      both eyes, and mCNV treated with ranibizumab 0.5 mg in one eye, who were
      retrospectively enrolled. Areas of CRA in treated and fellow eyes were measured
      on fundus autofluorescence images at baseline, 12, and 24 months. The CRA
      hypoautofluorescent lesions were divided in two groups: perilesional atrophy,
      corresponding to area around the mCNV, and patchy extralesional atrophy,
      corresponding to CRA between the temporal vascular arcades. Results: Thirty-six
      eyes of 18 patients were included. The mean perilesional CRA size significantly
      increased from baseline to 12 months (3.5 +/- 10.6 mm2, P = 0.02) and 24 months
      (4.4 +/- 11.7 mm2, P = 0.038) in the treated eye. In treated and not treated
      eyes, patchy extralesional CRA at the posterior pole increased significantly from
      baseline to 12 and 24 months follow-up. None of the fellow eyes developed mCNV.
      No significant relationship was found between the number of injections, AxL, age,
      and perilesional and patchy extralesional CRA in the treated and not treated eyes
      (P > 0.05). Conclusions: In eyes with pathologic myopia and mCNV, intravitreal
      injections of ranibizumab should not be considered as a contributing risk factor 
      worsening the natural course of CRA, even though the risk of the perilesional CRA
      enlargement should be taken into account.
FAU - Parravano, Mariacristina
AU  - Parravano M
AD  - Fondazione G.B. Bietti-IRCCS, Rome, Italy.
FAU - Scarinci, Fabio
AU  - Scarinci F
AD  - Fondazione G.B. Bietti-IRCCS, Rome, Italy.
FAU - Gilardi, Marta
AU  - Gilardi M
AD  - Fondazione G.B. Bietti-IRCCS, Rome, Italy.
FAU - Querques, Lea
AU  - Querques L
AD  - Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University 
      Vita-Salute San Raffaele, Milan, Italy.
FAU - Varano, Monica
AU  - Varano M
AD  - Fondazione G.B. Bietti-IRCCS, Rome, Italy.
FAU - Oddone, Francesco
AU  - Oddone F
AD  - Fondazione G.B. Bietti-IRCCS, Rome, Italy.
FAU - Bandello, Francesco
AU  - Bandello F
AD  - Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University 
      Vita-Salute San Raffaele, Milan, Italy.
FAU - Querques, Giuseppe
AU  - Querques G
AD  - Fondazione G.B. Bietti-IRCCS, Rome, Italy.
AD  - Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, University 
      Vita-Salute San Raffaele, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Angiogenesis Inhibitors)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Atrophy
MH  - Choroid/pathology
MH  - Choroidal Neovascularization/*drug therapy/pathology
MH  - Female
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Myopia, Degenerative/*drug therapy/pathology
MH  - Ranibizumab/*therapeutic use
MH  - Retina/pathology
MH  - Retrospective Studies
EDAT- 2017/12/21 06:00
MHDA- 2017/12/28 06:00
CRDT- 2017/12/21 06:00
PHST- 2017/12/21 06:00 [entrez]
PHST- 2017/12/21 06:00 [pubmed]
PHST- 2017/12/28 06:00 [medline]
AID - 2667032 [pii]
AID - 10.1167/iovs.17-22633 [doi]
PST - ppublish
SO  - Invest Ophthalmol Vis Sci. 2017 Dec 1;58(14):6358-6364. doi:
      10.1167/iovs.17-22633.